Tools · Private company · Framingham, MA, US
Kephera Diagnostics, LLC
Track this companyFree. Adds Kephera Diagnostics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Rapid Diagnostic Immunoassay for StrongyloidiasisFiscal year 2026 · $303.3KNIH RePORTER 1R43AI186917-01A1 · fetched Nov 12, 2026
- Peptide-based ELISA for laboratory diagnosis of sarcoidosisFiscal year 2026 · $1MNIH RePORTER 5R44HL180181-02 · fetched Nov 12, 2026
- Peptide-based ELISA for laboratory diagnosis of sarcoidosisFiscal year 2025 · $978.2KNIH RePORTER 1R44HL180181-01 · fetched Nov 12, 2026
- Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure PatientsFiscal year 2025 · $123.6KNIH RePORTER 3R44AI149903-05S1 · fetched Nov 12, 2026
- Diagnostic assay for congenital Chagas diseaseFiscal year 2025 · $303.3KNIH RePORTER 5R43AI181234-02 · fetched Nov 12, 2026
- Point-of-care diagnostic test for T. cruzi (Chagas) infectionFiscal year 2025 · $1MNIH RePORTER 5R44AI136172-05 · fetched Nov 12, 2026
- Hybrid ELISA: Simple and specific one-tier assay for Lyme diseaseFiscal year 2025 · $714.7KNIH RePORTER 5R44AI142903-05 · fetched Nov 12, 2026
- Biomarker-Based Test of Cure for Chagas DiseaseFiscal year 2025 · $906KNIH RePORTER 5R44AI147973-05 · fetched Nov 12, 2026
- Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure PatientsFiscal year 2025 · $876.4KNIH RePORTER 5R44AI149903-05 · fetched Nov 12, 2026
- NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR SELECT NEGLECTED TROPICAL DISEASES Fiscal year 2025 · $300KNIH RePORTER 75N93025C00003-0-9999-1 · fetched Nov 12, 2026